SARcopenia and Simplified Geriatric Assessment in Lymphoma Patients Undergoing CAR-T Cell Therapy: the FIL_SAR-CAR Project

Fondazione Italiana Linfomi - ETS

Status: Enrolling

Conditions: Non-hodgkin Lymphoma,B Cell

Treatments: Other: Chimeric Antigen Receptor T-cells (CAR-T) therapy

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT06156774

FIL_SAR-CAR

Details and patient eligibility

About

This is a multicenter prospective observational study lead by the FIL on sarcopenia and sGA as possible predictors of efficacy and toxicity outcomes in patients undergoing CAR-T cells treatment.

Enrollment: 130 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adult patients (≥ 18 years old).
• Patients with B-cell non-Hodgkin Lymphoma scheduled to received CAR-T cell product according to Agenzia Italiana del Farmaco (AIFA) indications and technical data sheet of the drug
• Availability of a 18F-FDG PET/CT scan or a full dose CT scan (without contrast media) pre-treatment with CART
• Written informed consent voluntarily provided

Exclusion criteria

• Patients not fulfilling the eligibility criteria

Trial design

130 participants in 1 patient group

Patients with Non-Hodgkin Lymphoma B cell

Description:

Patients with B-cell non-Hodgkin Lymphoma scheduled to received CAR-T cell product according to Agenzia Italiana del Farmaco (AIFA) indications and technical data sheet of the drug

Treatment:

Other: Chimeric Antigen Receptor T-cells (CAR-T) therapy